ChiCTR2600116167 版本V1.0 版本创建时间2026/01/06 14:52:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600116167 

最近更新日期:

Date of Last Refreshed on:

2026-01-06 14:52:08 

注册时间:

Date of Registration:

2026-01-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

激光疗法联合PNF技术治疗膝关节骨性关节炎疼痛的临床研究

Public title:

Clinical Study on Laser Therapy Combined with PNF Technique for Treating Pain in Knee Osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

激光疗法联合PNF技术治疗膝关节骨性关节炎疼痛的临床研究

Scientific title:

Clinical Study on Laser Therapy Combined with PNF Technique for Treating Pain in Knee Osteoarthritis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

朱炜楷 

研究负责人:

朱炜楷 

Applicant:

Zhu Weikai 

Study leader:

Zhu Weikai 

申请注册联系人电话:

Applicant telephone:

+86 411 8363 5963

研究负责人电话:

Study leader's telephone:

+86 411 8363 5963

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhuwk1018@126.com

研究负责人电子邮件:

Study leader's E-mail:

zhuwk1018@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省大连市西岗区中山路222号

研究负责人通讯地址:

辽宁省大连市西岗区中山路222号

Applicant address:

No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province

Study leader's address:

No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

大连医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Dalian Medical University

研究负责人所在单位:

大连医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Dalian Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

PJ-KS-KY-2025-957(X)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

大连医科大学附属第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of The First Affiliated Hospital of Dalian Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-18 00:00:00

伦理委员会联系人:

徐蕾

Contact Name of the ethic committee:

Xu Lei

伦理委员会联系地址:

辽宁省大连市西岗区中山路222号

Contact Address of the ethic committee:

No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 411 83010706

伦理委员会联系人邮箱:

Contact email of the ethic committee:

dyyyirb@163.com

研究实施负责(组长)单位:

大连医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Dalian Medical University

研究实施负责(组长)单位地址:

辽宁省大连市西岗区中山路222号

Primary sponsor's address:

No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁省

市(区县):

Country:

China

Province:

Liaoning

City:

单位(医院):

大连医科大学附属第一医院

具体地址:

辽宁省大连市西岗区中山路222号

Institution
hospital:

The First Affiliated Hospital of Dalian Medical University

Address:

No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province

经费或物资来源:

Source(s) of funding:

None

Target disease:

Knee osteoarthritis

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

主要目的:验证激光疗法联合PNF技术在治疗膝关节骨性关节炎疼痛中的协同效应,评估其在疼痛缓解、功能改善和长期疗效维持方面的临床优势。  

Objectives of Study:

Primary Objective: To verify the synergistic effects of laser therapy combined with PNF techniques in the treatment of knee osteoarthritis pain, and to evaluate its clinical advantages in pain relief, functional improvement, and long-term efficacy maintenance.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄50-75岁,性别不限; 2.符合膝骨关节炎诊断标准或慢性膝关节软组织损伤诊断; 3.视觉模拟评分(VAS)>=4分,病程>=3个月; 4.签署知情同意且能够完成康复评估和训练计划。

Inclusion criteria

1. Age: 50-75 years old, gender not limited; 2. Meet the diagnostic criteria for knee osteoarthritis or the diagnosis of chronic soft tissue injury of the knee joint; 3. Visual Analogue Scale (VAS) score >=4 points, disease duration >=3 months; 4. Sign informed consent and be able to complete the rehabilitation assessment and training plan.

排除标准:

1.严重骨质疏松(T值<=-3.0)或关节畸形; 2.3个月内接受过关节腔注射治疗; 3.合并严重心脑血管疾病(NYHA分级Ⅲ-Ⅳ级); 4.认知功能障碍(MMSE评分<=24分); 5.光过敏或运动疗法禁忌证。

Exclusion criteria:

1. Severe osteoporosis (T value <=-3.0) or joint deformity; 2. Received intra-articular injection treatment within 3 months; 3. Combined with severe cardiovascular and cerebrovascular diseases (NYHA grade Ⅲ-Ⅳ); 4. Cognitive dysfunction (MMSE score <= 24 points); 5. Contraindications for photosensitivity or exercise therapy.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-06 00:00:00 To 2026-12-31 00:00:00  

干预措施:

Interventions:

组别:

联合治疗组

样本量:

25

Group:

Combined treatment group

Sample size:

干预措施:

激光联合PNF治疗

干预措施代码:

Intervention:

Laser combined with PNF treatment

Intervention code:

组别:

PNF治疗组

样本量:

25

Group:

PNF treatment group

Sample size:

干预措施:

PNF治疗

干预措施代码:

Intervention:

PNF treatment

Intervention code:

组别:

激光治疗组

样本量:

25

Group:

Laser Therapy Group

Sample size:

干预措施:

激光治疗

干预措施代码:

Intervention:

Laser Therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁省 

市(区县):

 

Country:

China 

Province:

Liaoning 

City:

 

单位(医院):

大连医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Dalian Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

关节活动度测量

指标类型:

次要指标

Outcome:

Range of Motion Measurement

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

Visual Analog Scale (VAS)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WOMAC 骨关节炎指数

指标类型:

主要指标

Outcome:

WOMAC Osteoarthritis Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌力评估

指标类型:

次要指标

Outcome:

Muscle strength assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

10米步行测试

指标类型:

次要指标

Outcome:

10-meter walk test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

2分钟步行距离测试

指标类型:

次要指标

Outcome:

Two-minute walking distance test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C-反应蛋白(CPR)炎症因子检测

指标类型:

次要指标

Outcome:

Detection of C-reactive protein (CPR) inflammatory factors

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者朱炜楷使用中央随机化系统 (IWRS)进行研究参与者的竞争入组及处理分组随机化的管理。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researcher Zhu Weikai utilized the Interactive Web Response System (IWRS) to manage competitive enrollment of study participants and randomization of treatment groups.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲,对研究参与者设盲

Blinding:

Single-blind, blinding the study participants

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-01-06 14:52:08